PKD Foundation of Canada - For Research in Polycystic Kidney Disease

Clinical Trials

Clinical trials are now exploring several new therapies for PKD. Patients wishing to participate or learn more will find specific information about the therapies below. To participate in a clinical trial, you will need to have a formal diagnosis of PKD. To learn more, click here.

mTOR Inhibitors

Rapamycin (Rapamune ®, Sirolimus) has been prescribed post-transplant to stop rejection of the new organ. Everolimus is a biochemically related compound. Both drugs have been found to inhibit cell growth in cysts by binding to a protein called mTor (mammalian target of rapamycin) in renal cells. As a result, cyst growth is reduced.

Blood Pressure Regulation Clinical Trials

HALT PKD Progression of PKD (HALT PKD)

Intervention:	Drugs - lisonopril, telmisartan
Sponsor:	University of Pittsburgh Medical center
Study Phase:	III
Status:	Active; enrollment complete
Enrollment goal:	1,018
Description:	To assess the effectiveness of anti-hypertensive drugs telmisartan and lisinopril on PKD progression and its cardiovascular complications in two different levels of kidney function, GFR more than 60 mL/min/1/73m^2 and GFR between 25-60 mL/min/1.73m^2.
Additional Information:	The Data Collection center is now located at the University of Pittsburgh Medical center.
Contact:
Website:	NIH Study Details

Effect of Statin Therapy on Disease Progression in ADPKD

Intervention:	Drug - Pravastatin
Sponsor:	University of Colorado Denver
Study Phase:	III
Status:	Active; enrollment complete
Age Group:	8-21
Enrollment goal:	100
Description:	To determine the effect of pravastatin treatment on renal and cardiovascular disease over a 3-year study period in children and young adults aged 8-21 years with ADPKD.
Contact:	Melissa Cadnapaphornchai, M.D. at 303-724-1690 or pkd.nurse@ucdenver.edu Linda Perkins at 303-724-1690 or pkd.nurse@ucdenver.edu. You may also call toll-free at 1-877-765-9297.
Website:	NIH Study Details

The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in ADPKD

Intervention:	Drug - High or low sodium diet
Sponsor:	Holstebro Hospital, Denmark
Status:	Recruiting
Age Group:	18-65
Enrollment goal:	25
Description:	To examine the effect of high and low diets on kidney function and on hormones that affect the kidney.
Contact:	Carolina Cannillo, M.D. at 1145099125428 or cacan@ringamt.dk
Website:	NIH Study Details

CCB Safety Study in Treatment of Hypertension in ADPKD

Intervention:	Drugs - Candesartan; Candesartan Cilnidipine; Candesartan non-calcium channel blocker (CCB)
Sponsor:	Kyorin University, Japan
Study Phase:	IV
Status:	Recruiting
Age Group:	20-60
Enrollment goal:	150
Description:	To evaluate the safety and efficacy of calcium channel blocker Candesartan in treatment of hypertension in ADPKD patients.
Contact:	Eiji Higashihara, M.D. at 81-422-47-5511, ext. 5813 or ehigashi@kyorin-u.ac.jp
Website:	NIH Study Details

Study for the Second Line Treatment of Hypertension in Patients With ADPKD

Intervention:	Drug - Candesartan, Cilnidipine, Imidapril
Sponsor:	The Ministry of Health, Labour & Welfare, Japan; Teikyo University
Study Phase:	II
Status:	Not yet Recruiting
Age Group:	20-60
Enrollment goal:	160
Description:	To compare the safety and effectiveness of combination therapy to control blood pressure in patients with ADPKD whose blood pressure is not controlled under 120/80 with ARB alone. Either ACE or CCB will be added to the regimen and results will be compared to those on ARB alone. ARB – angiotensin receptor blocker ACE – angiotensin converting enzyme inhibitor CCB – Calcium channel blocker
Contact:	Shigeo Horie, MD at +81339642497shorie@med.teikyo-u.ac.jp Satoru Muto, MD, PhD at +81339642497muto@med.teiku-u.ac.jp
Website:	NIH Study Details